FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Summary
The FDA approved Myqorzo (aficamten), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Obstructive HCM is a common inherited heart condition in which the heart muscle thickens abnormally, obstructing blood flow and causing symptoms like shortness of breath, chest pain, and reduced exercise tolerance. Aficamten works by directly reducing the number of active myosin-actin cross-bridges in heart muscle cells, thereby decreasing the excessive contractility that drives obstruction. This represents a targeted, mechanism-based approach distinct from older symptom-management strategies like beta-blockers or calcium channel blockers. The approval marks a significant step for a condition that has historically had limited pharmacological options, with surgery or alcohol septal ablation reserved for refractory cases.
Detailed Summary
Hypertrophic cardiomyopathy affects roughly 1 in 500 people and is the most common inherited heart disease. The obstructive form, in which the thickened septum impedes left ventricular outflow, is responsible for the majority of symptoms and adverse outcomes. Until recently, treatment options were limited to general rate-control agents or invasive procedures, leaving a significant unmet need for targeted therapies.
Aficamten, marketed as Myqorzo by Cytokinetics and developed in collaboration with Johnson & Johnson, is a selective cardiac myosin inhibitor. It reduces excessive myocardial contractility by decreasing the number of actin-myosin cross-bridge formations during each cardiac cycle. This directly addresses the pathophysiological mechanism driving left ventricular outflow tract obstruction in HCM.
The FDA approval, granted on December 19, 2025, was based on clinical trial data demonstrating meaningful reductions in left ventricular outflow tract gradients and improvements in functional capacity and symptom burden. Aficamten joins mavacamten as only the second cardiac myosin inhibitor approved for obstructive HCM, offering an alternative for patients who may not tolerate or respond adequately to first-in-class therapy.
For clinicians managing HCM, aficamten's approval expands the pharmacological toolkit meaningfully. Patients with symptomatic obstructive HCM who remain limited on standard agents now have a second mechanistically targeted option before escalating to septal reduction procedures. Monitoring for excessive negative inotropy and reduced ejection fraction will remain important safety considerations.
Caveats include the fact that this summary is based on a secondary source and abstract-level information rather than full prescribing information or primary trial publications. The precise patient selection criteria, dosing regimen, contraindications, and head-to-head data versus mavacamten require review of full FDA labeling and supporting trial data before clinical application.
Key Findings
- Aficamten (Myqorzo) received FDA approval December 19, 2025 for symptomatic obstructive hypertrophic cardiomyopathy.
- Mechanism targets cardiac myosin directly, reducing excessive contractility and left ventricular outflow obstruction.
- Aficamten is only the second cardiac myosin inhibitor approved for obstructive HCM after mavacamten.
- Approval expands pharmacological options for patients inadequately controlled on beta-blockers or calcium channel blockers.
- Safety monitoring for excessive negative inotropy and ejection fraction reduction is required during therapy.
Methodology
Approval was based on clinical trial evidence submitted to the FDA; specific trial design, endpoints, and patient populations are not fully detailed in the available abstract-level source. The pivotal trial data likely included echocardiographic measures of LVOT gradient and functional capacity assessments. Full methodology requires review of primary trial publications and FDA prescribing information.
Study Limitations
This summary is based on the abstract and a secondary news source only; full prescribing information, trial methodology, efficacy endpoints, and safety data were not available for review. The source article appears to conflate multiple recent FDA approvals, introducing uncertainty about specific approval details for aficamten. Clinicians should consult the full FDA label and primary trial publications before prescribing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.